Semax: What the Evidence Actually Shows

Semax is marketed as a nootropic — a "cognitive enhancement" peptide, sold overwhelmingly as a nasal spray rather than an injectable. Unlike most of the compounds in this site's newest research batch, it isn't a research-chemical-market invention with no clinical history: it has a genuine, decades-long human research record out of Russian neuroscience. What it does not have is any FDA approval, or a settled U.S. compounding status.

What it is, and why it isn't hormonally active despite its name

Semax is a synthetic heptapeptide — Met-Glu-His-Phe-Pro-Gly-Pro — built as an analog of ACTH(4-10), a fragment of adrenocorticotropic hormone. That lineage is where the "ACTH" name in some of the scientific literature comes from, and it's also the source of a common misconception: full-length ACTH stimulates the adrenal glands to release cortisol, but the melanocortin-receptor-binding region responsible for that hormonal effect isn't in this fragment. Semax's researched effects are neurotrophic, not endocrine — most centrally, upregulating brain-derived neurotrophic factor (BDNF). A rat study found Semax "binds specifically and increases levels of brain-derived neurotrophic factor protein" in the basal forebrain², and more recent rat work continues to find the same protective gene-expression pattern in models of cerebral ischemia³. This research line goes back further than almost any other compound in this site's corpus: a 1997 paper already describes "15 years experience in its design and study"¹, placing Semax's origin in early-1980s Russian neuroscience research.

The human evidence: real, but not a placebo-controlled trial

The most substantial human study located for this article is a 2018 Russian trial of 110 ischemic-stroke patients, split into early- and late-rehabilitation groups and further subdivided by whether they received Semax. Patients who received Semax showed a faster, more sustained rise in plasma BDNF, and that BDNF response correlated with better functional recovery on the Barthel Index, a standard activities-of-daily-living scale⁴. Read this plainly for what it is: a real, 110-patient human study using an objective biomarker (plasma BDNF) and a validated functional outcome measure — genuinely more substantial than what most of this site's non-board compounds have behind them. It is also not a randomized, placebo-controlled trial; patients were divided into subgroups by treatment status and rehabilitation timing, not randomized to Semax versus placebo. Both facts belong in the same sentence.

The regulatory picture — and a real discrepancy this article found, not resolved

Semax's U.S. regulatory status is genuinely unsettled, and two FDA documents disagree with each other in a way this article states directly rather than picking a side on. FDA's current, officially categorized 503A Bulks List — updated May 14, 2026, fetched fresh and text-searched for this article — contains no mention of Semax in Category 1, 2, or 3⁵. But FDA's companion descriptive page, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks," still lists a "Semax (heptapeptide)" row today, fetched live for this article, with the same immunogenicity-based concern language FDA applies broadly across this list: "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities... FDA has no, or limited, safety-related information"⁶. One document omits Semax entirely; the other still names it. This article does not attempt to resolve which is the more current source of truth — it reports both, live-fetched the same day.

Separately, and independently reconfirmed by fetching FDA's own advisory-committee calendar for this article, Semax was formally reviewed at FDA's Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, alongside DSIP/Emideltide and Epitalon — the agenda item names the specific nominated uses under evaluation: "Cerebral ischemia, migraine, and trigeminal neuralgia"⁷. That confirms the meeting and Semax's presence on it; it does not, on its own, establish the vote outcome, which this article did not independently re-derive from a primary vote-record document.

The safety signal that exists — and it's thin

DailyMed's structured-product-label search returns zero results for "Semax," confirming no FDA-approved drug product exists under that name⁸. openFDA's FAERS adverse-event database returns 2 total reports naming Semax⁹ — too small a number to compute any incidence rate from, and, read honestly, this reflects thin real-world reporting for a compounded product rather than a demonstrated safety profile in either direction.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Semax as a primary, boarded product — this site's own identity-layer research confirms it is not tagged to any reviewed seller. Semax is overwhelmingly sold and administered as a nasal spray rather than an injectable — even vendors offering a lyophilized-powder "vial" package it as a nasal-spray kit rather than a standalone injectable, which is why this site does not carry a Semax reconstitution calculator, the same finding this site's DSIP calculator page already reached when it investigated Semax as a possible sibling page and built /calculator/melanotan-ii instead. Semax's own human evidence is genuinely more substantial than most of the compounds covered in this same research batch, but it comes from a single non-randomized comparison study, not a placebo-controlled trial, and its U.S. regulatory status is unsettled rather than resolved — two federal documents that, as of this article's own live check, do not agree with each other.